via Wistar Institute
Wistar Institute scientists have discovered a new class of compounds that uniquely combine direct antibiotic killing of pan drug-resistant bacterial pathogens with a simultaneous rapid immune response for combatting antimicrobial resistance (AMR).
These finding were published today in Nature.
The World Health Organization (WHO) has declared AMR as one of the top 10 global public health threats against humanity. It is estimated that by 2050, antibiotic-resistant infections could claim 10 million lives each year and impose a cumulative $100 trillion burden on the global economy. The list of bacteria that are becoming resistant to treatment with all available antibiotic options is growing and few new drugs are in the pipeline, creating a pressing need for new classes of antibiotics to prevent public health crises.
“We took a creative, double-pronged strategy to develop new molecules that can kill difficult-to-treat infections while enhancing the natural host immune response,” said Farokh Dotiwala, M.B.B.S., Ph.D., assistant professor in the Vaccine & Immunotherapy Center and lead author of the effort to identify a new generation of antimicrobials named dual-acting immuno-antibiotics (DAIAs).
Existing antibiotics target essential bacterial functions, including nucleic acid and protein synthesis, building of the cell membrane, and metabolic pathways. However, bacteria can acquire drug resistance by mutating the bacterial target the antibiotic is directed against, inactivating the drugs or pumping them out.
“We reasoned that harnessing the immune system to simultaneously attack bacteria on two different fronts makes it hard for them to develop resistance,” said Dotiwala.
He and colleagues focused on a metabolic pathway that is essential for most bacteria but absent in humans, making it an ideal target for antibiotic development. This pathway, called methyl-D-erythritol phosphate (MEP) or non-mevalonate pathway, is responsible for biosynthesis of isoprenoids — molecules required for cell survival in most pathogenic bacteria. The lab targeted the IspH enzyme, an essential enzyme in isoprenoid biosynthesis, as a way to block this pathway and kill the microbes. Given the broad presence of IspH in the bacterial world, this approach may target a wide range of bacteria.
Researchers used computer modeling to screen several million commercially available compounds for their ability to bind with the enzyme, and selected the most potent ones that inhibited IspH function as starting points for drug discovery.
Since previously available IspH inhibitors could not penetrate the bacterial cell wall, Dotiwala collaborated with Wistar’s medicinal chemist Joseph Salvino, Ph.D., professor in The Wistar Institute Cancer Center and a co-senior author on the study, to identify and synthesize novel IspH inhibitor molecules that were able to get inside the bacteria.
The team demonstrated that the IspH inhibitors stimulated the immune system with more potent bacterial killing activity and specificity than current best-in-class antibiotics when tested in vitro on clinical isolates of antibiotic-resistant bacteria, including a wide range of pathogenic gram negative and gram positive bacteria. In preclinical models of gram negative bacterial infection, the bactericidal effects of the IspH inhibitors outperformed traditional pan antibiotics. All compounds tested were shown to be nontoxic to human cells.
“Immune activation represents the second line of attack of the DAIA strategy,” said Kumar Singh, Ph.D., Dotiwala lab postdoctoral fellow and first author of the study.
“We believe this innovative DAIA strategy may represent a potential landmark in the world’s fight against AMR, creating a synergy between the direct killing ability of antibiotics and the natural power of the immune system,” echoed Dotiwala.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
New class of antibiotics
- Psychedelic Toad Venom Shows Promise for New Depression Treatment
Scientists have mapped the structure of a psychedelic drug derived from the Colorado River toad, which seems to have antidepressant effects.
- ‘Ozempic babies’: Reports of surprise pregnancies raise new questions about weight loss drugs
I was depressed, severely depressed for that whole time.” Five months earlier, in October 2022, Bentley had started taking Mounjaro for weight loss. Over the first few months, she said, she lost about ...
- The 25 Most Popular Drugs by U.S. Spending
Help Register Login Login Hi, %{firstName}% Hi, %{firstName}% Games Car rental The United States spent a total of more than $722 billion on prescription drugs in 2023, a new report finds. That’s a ...
- Recce Pharmaceuticals Granted New Patent in China for RECCE® Anti-Infectives
2 About Recce Pharmaceuticals Ltd Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of ...
- New Cancer 'Missile' Drugs May Be More Effective Than Traditional Chemotherapy
Antibody-drug conjugates are a new type of cancer therapy that deliver cancer-killing medicine to cancer cells, avoiding healthy cells along the way.
Go deeper with Google Headlines on:
New class of antibiotics
[google_news title=”” keyword=”new class of antibiotics” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Drug-resistant bacterial pathogens
- 3 BRILLIANT MINUTES: Bacteria and antibiotics
We learn more about how it works and learn of its benefits. Additionally, antibiotic-resistant bacteria, never seen here on Earth, has been found on the International Space Station. The video above ...
- Researchers target spermidine production to combat emerging drug resistance in Salmonella
Food-borne diseases like typhoid, caused by Salmonella Typhimurium, are a severe threat to public health, especially in India. The indiscriminate use of antibiotics has allowed this bacterium to ...
- Study underscores new strategies to fight drug-resistant bacteria
Several billion years ago, a genetic arms race began between bacteria and their viral killers. This seemingly eternal struggle continues today, with implications for diseases killing tens of thousands ...
- Fred Allendorf: Science and Nature: Evolution of antibiotic resistance in bacteria
Approximately 8 million people die annually around the world from infectious diseases caused by bacteria. Bacterial diseases have been the major cause of human mortality throughout history. For ...
- A mother's loss launches a global effort to fight antibiotic resistance
Diane Shader Smith's daughter, Mallory Smith, died at age 25 after fighting an antibiotic-resistant lung infection for 12 years. A new book of her daughter's diary entries and a website are aimed at ...
Go deeper with Google Headlines on:
Drug-resistant bacterial pathogens
[google_news title=”” keyword=”drug-resistant bacterial pathogens” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]